复古的胜利:华法林对抗阿皮克萨班在抗脂竞技场
Michael Sabina1, Zein Barakat1, Bernardo Costa Guerra1
1Internal Medicine, Lakeland Regional Health Medical Center, Lakeland, USA.
Cureus
|April 29, 2024
概括
华法林在治疗抗脂综合征 (APS) 时表现出有效性,当阿皮克萨班失败时. 这一案例突显了华法林的存在.
科学领域:
- 内部医学 内部医学
- 血液学 血液学 血液学
- 类风湿病学 类风湿病学
背景情况:
- 抗脂综合征 (APS) 是一种与复发性血栓相关的自身免疫性疾病.
- 治疗APS通常涉及抗凝固疗法.
- 直接口服抗凝剂 (DOAC) 越来越多地使用,但它们在APS中的有效性仍有争议.
研究的目的:
- 为了在患有抗脂综合征的患者中比较华法林与阿皮克萨班的疗效.
- 突出在APS管理中DOACs的潜在局限性.
- 为讨论APS最佳抗凝策略做出贡献.
主要方法:
- 一个41岁的女性患有APS的病例报告.
- 初始治疗用阿皮克萨班,一个DOAC.
- 由于对阿皮克萨班缺乏反应,转换为华法林治疗.
主要成果:
- 患者对阿皮克萨班治疗没有反应.
- 转换为华法林导致症状的缓解.
- 在华法林治疗期间没有观察到进一步的血栓事件或并发症.
结论:
- 华法林可能是比阿皮克萨班更有效的抗凝剂,用于治疗抗脂综合征.
- 像阿皮克萨班这样的DOAC可能对APS治疗有限制.
- 需要进一步的研究来确定APS患者的最佳抗凝剂.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
Disorders of Hemostasis
872
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
872
Therapeutic Index
4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K


